ADC Therapeutics SA expected to post a loss of 86  cents a share - Earnings Preview

ADC Therapeutics SA

01/03/2022 11:12

* ADC Therapeutics SA  ADCT.N   ADCT.K  is expected to show
a rise
in quarterly revenue when it reports  results on March 3. 
    * The Epalinges Vaud-based  company is expected to report
revenue
of $16.458 million, according to the mean estimate from 6
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for ADC Therapeutics SA
is
for a loss of 86 cents per share. For the same quarter last
year, the company reported a loss of $1.05 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $41​, about 59.3% above​ its last closing price
of $16.70. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.96       -0.92      -0.93     Missed  -1.4
 Jun. 30 2021  -0.87       -0.86      -0.96     Missed  -11.6
 Mar. 31 2021  -0.92       -0.90      -0.46     Beat    49.2​
 Dec. 31 2020  -0.14       -0.38      -1.05     Missed  -173.9
 ​​Sep.        -0.83       -0.81      -0.77     Beat    4.9
 30 2020                                                
 Jun. 30 2020  -0.65       -0.65      -0.73     Missed  -12.3​
 Mar. 31 2020              -0.67                        
 This summary was machine generated March 1 at 11:12 GMT.  All
figures in US dollars  unless otherwise stated